1
|
Morris J, Takahashi-Ruiz L, Persi LN, Summers JC, McCauley EP, Chan PYW, Amberchan G, Lizama-Chamu I, Coppage DA, Crews P, Risinger AL, Johnson TA. Re-evaluation of the Fijianolide/Laulimalide Chemotype Suggests an Alternate Mechanism of Action for C-15/C-20 Analogs. ACS OMEGA 2022; 7:8824-8832. [PMID: 35309480 PMCID: PMC8928504 DOI: 10.1021/acsomega.1c07146] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/18/2021] [Accepted: 02/23/2022] [Indexed: 06/14/2023]
Abstract
Herein, we report on naturally derived microtubule stabilizers with activity against triple negative breast cancer (TNBC) cell lines, including paclitaxel, fijianolide B/laulimalide (3), fijianolide B di-acetate (4), and two new semisynthetic analogs of 3, which include fijianolide J (5) and fijianolide L (6). Similar to paclitaxel, compound 3 demonstrated classic microtubule stabilizing activity with potent (GI50 = 0.7-17 nM) antiproliferative efficacy among the five molecularly distinct TNBC cell lines. Alternatively, compounds 5 or 6, generated from oxidation of C-20 or C-15 and C-20 respectively, resulted in a unique profile with reduced potency (GI50 = 4-9 μM), but improved efficacy in some lines, suggesting a distinct mechanism of action. The C-15, C-20 di-acetate, and dioxo modifications on 4 and 6 resulted in compounds devoid of classic microtubule stabilizing activity in biochemical assays. While 4 also had no detectable effect on cellular microtubules, 6 promoted a reorganization of the cytoskeleton resulting in an accumulation of microtubules at the cell periphery. Compound 5, with a single C-20 oxo substitution, displayed a mixed phenotype, sharing properties of 3 and 6. These results demonstrate the importance of the C-15/C-20 chiral centers, which appear to be required for the potent microtubule stabilizing activity of this chemotype and that oxidation of these sites promotes unanticipated cytoskeletal alterations that are distinct from classic microtubule stabilization, likely through a distinct mechanism of action.
Collapse
Affiliation(s)
- Joseph
D. Morris
- Department
of Natural Sciences, Dominican University
of California, San Rafael, California 94901, United States
| | - Leila Takahashi-Ruiz
- Department
of Pharmacology, University of Texas Health
Science Center at San Antonio, San Antonio, Texas 78229, United States
| | - Lauren N. Persi
- Department
of Natural Sciences, Dominican University
of California, San Rafael, California 94901, United States
| | - Jonathan C. Summers
- Department
of Natural Sciences, Dominican University
of California, San Rafael, California 94901, United States
| | - Erin P. McCauley
- Department
of Chemistry & Biochemistry, University
of California, Santa Cruz, California 95064, United States
| | - Peter Y. W. Chan
- Department
of Pharmacology, University of Texas Health
Science Center at San Antonio, San Antonio, Texas 78229, United States
| | - Gabriella Amberchan
- Department
of Chemistry & Biochemistry, University
of California, Santa Cruz, California 95064, United States
| | - Itzel Lizama-Chamu
- Department
of Chemistry & Biochemistry, University
of California, Santa Cruz, California 95064, United States
| | - David A. Coppage
- Department
of Chemistry & Biochemistry, University
of California, Santa Cruz, California 95064, United States
| | - Phillip Crews
- Department
of Chemistry & Biochemistry, University
of California, Santa Cruz, California 95064, United States
| | - April L. Risinger
- Department
of Pharmacology, University of Texas Health
Science Center at San Antonio, San Antonio, Texas 78229, United States
| | - Tyler A. Johnson
- Department
of Natural Sciences, Dominican University
of California, San Rafael, California 94901, United States
- Department
of Chemistry & Biochemistry, University
of California, Santa Cruz, California 95064, United States
| |
Collapse
|
2
|
Olatunde OZ, Yong J, Lu C. The Progress of the Anticancer Agents Related to the Microtubules Target. Mini Rev Med Chem 2020; 20:2165-2192. [PMID: 32727327 DOI: 10.2174/1389557520666200729162510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 05/11/2020] [Accepted: 05/22/2020] [Indexed: 11/22/2022]
Abstract
Anticancer drugs based on the microtubules target are potent mitotic spindle poison agents, which interact directly with the microtubules, and were classified as microtubule-stabilizing agents and microtubule-destabilizing agents. Researchers have worked tremendously towards the improvements of anticancer drugs, in terms of improving the efficacy, solubility and reducing the side effects, which brought about advancement in chemotherapy. In this review, we focused on describing the discovery, structures and functions of the microtubules as well as the progress of anticancer agents related to the microtubules, which will provide adequate references for researchers.
Collapse
Affiliation(s)
- Olagoke Zacchaeus Olatunde
- CAS Key Laboratory of Desing and Assembly of Functional Nanostructures, and Fujian Provincial Key Laboratory of Nanomaterials, Fujian Institute of Research on the Structures of Matter, Chinese Academy of Sciences. Fuzhou, Fujian, 350002, China
| | - Jianping Yong
- Xiamen Institute of Rare-Earth Materials, Chinese Academy of Sciences, Xiamen, Fujian, 361021, China
| | - Canzhong Lu
- CAS Key Laboratory of Desing and Assembly of Functional Nanostructures, and Fujian Provincial Key Laboratory of Nanomaterials, Fujian Institute of Research on the Structures of Matter, Chinese Academy of Sciences. Fuzhou, Fujian, 350002, China
| |
Collapse
|
3
|
Tien AC, Li J, Bao X, Derogatis A, Kim S, Mehta S, Sanai N. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort. Clin Cancer Res 2019; 25:5777-5786. [PMID: 31285369 PMCID: PMC6863147 DOI: 10.1158/1078-0432.ccr-19-0133] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 04/14/2019] [Accepted: 07/02/2019] [Indexed: 01/01/2023]
Abstract
PURPOSE CDK4/6-dependent cell-cycle regulation is disrupted in most glioblastomas. This study assesses the central nervous system (CNS) pharmacokinetics and tumor pharmacodynamics of ribociclib, a highly selective CDK4/6 inhibitor, in patients with recurrent glioblastoma. PATIENTS AND METHODS Patients with recurrent glioblastoma with intact retinoblastoma protein (RB) expression and CDKN2A deletion or CDK4/6 amplification were treated with ribociclib daily (900 mg) for 5 days before tumor resection. Blood, tumor, and cerebrospinal fluid (CSF) samples were collected, and total and unbound ribociclib concentrations were determined. Pharmacodynamic effects, assessed by RB and FOXM1 phosphorylation, were compared with matched archival tissue. Patients with positive pharmacokinetic and pharmacodynamic effects were enrolled into the expansion cohort for preliminary assessment of progression-free survival (PFS). RESULTS Twelve patients were enrolled. The mean unbound ribociclib concentrations in CSF, nonenhancing, and enhancing tumor regions were 0.374 μmol/L, 0.560, and 2.152 μmol/kg, respectively, which were more than 5-fold the in vitro IC50 for inhibition of CDK4/6 (0.04 μmol/L). G1-to-S phase suppression was inferred by decreases in phosphorylation of RB (P < 0.01) and cellular proliferation (P < 0.05). Six of 12 patients were enrolled into the pharmacokinetic/pharmacodynamic-guided expansion cohort and demonstrated a median PFS of 9.7 weeks. Examination of recurrent tumors following monotherapy indicated upregulation of the PI3K/mTOR pathway. CONCLUSIONS Ribociclib exhibited good CNS penetration, and target modulation was indicated by inhibition of RB phosphorylation and tumor proliferation. Ribociclib monotherapy showed limited clinical efficacy in patients with recurrent glioblastoma. Combination therapy with CDK4/6 and PI3K/mTOR inhibitors may be explored for treating recurrent glioblastoma.
Collapse
Affiliation(s)
- An-Chi Tien
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, Arizona
| | - Jing Li
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, Arizona
- Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
| | - Xun Bao
- Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
| | - Alanna Derogatis
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, Arizona
| | - Seongho Kim
- Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
| | - Shwetal Mehta
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, Arizona
| | - Nader Sanai
- Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, Arizona.
| |
Collapse
|
4
|
Miller JH, Field JJ, Kanakkanthara A, Owen JG, Singh AJ, Northcote PT. Marine Invertebrate Natural Products that Target Microtubules. JOURNAL OF NATURAL PRODUCTS 2018; 81:691-702. [PMID: 29431439 DOI: 10.1021/acs.jnatprod.7b00964] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Marine natural products as secondary metabolites are a potential major source of new drugs for treating disease. In some cases, cytotoxic marine metabolites target the microtubules of the eukaryote cytoskeleton for reasons that will be discussed. This review covers the microtubule-targeting agents reported from sponges, corals, tunicates, and molluscs and the evidence that many of these secondary metabolites are produced by bacterial symbionts. The review finishes by discussing the directions for future development and production of clinically relevant amounts of these natural products and their analogues through aquaculture, chemical synthesis, and biosynthesis by bacterial symbionts.
Collapse
Affiliation(s)
| | | | - Arun Kanakkanthara
- Department of Oncology and Department of Molecular Pharmacology and Experimental Therapeutics , Mayo Clinic , Rochester , Minnesota , United States
| | | | | | | |
Collapse
|
5
|
Mineeva IV. Cyclopropanol intermediates in the synthesis of the C5–C14 fragment of laulimalides. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2016. [DOI: 10.1134/s1070428016030118] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
6
|
Churchill CD, Klobukowski M, Tuszynski JA. Analysis of the binding mode of laulimalide to microtubules: Establishing a laulimalide–tubulin pharmacophore. J Biomol Struct Dyn 2016; 34:1455-69. [DOI: 10.1080/07391102.2015.1078115] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Cassandra D.M. Churchill
- Department of Chemistry, University of Alberta, 11227 Saskatchewan Drive, Edmonton, Alberta, Canada T6G 2G2
| | - Mariusz Klobukowski
- Department of Chemistry, University of Alberta, 11227 Saskatchewan Drive, Edmonton, Alberta, Canada T6G 2G2
| | - Jack A. Tuszynski
- Department of Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2
| |
Collapse
|
7
|
βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability. Cancer Lett 2015; 365:251-60. [PMID: 26052091 DOI: 10.1016/j.canlet.2015.06.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 05/21/2015] [Accepted: 06/01/2015] [Indexed: 01/04/2023]
Abstract
Peloruside A (PLA) and laulimalide (LAU) are potent microtubule-stabilizing natural products that are effective against a broad spectrum of cancer cells. The interactions of PLA and LAU with tubulin have attracted a great deal of attention, mainly because they bind to β-tubulin at a site that is different from the classical taxoid site. Multiple βI-tubulin amino acid residues have been predicted by computer modelling studies and more recently by protein crystallography to participate in the binding of PLA and LAU to tubulin. The relevance of these residues in determining cellular sensitivity to the compounds, however, remains largely uncertain. To determine the role of four binding site residues, Q291, D295, V333, and N337 on PLA and LAU activity, we introduced single mutations to these sites by site-directed mutagenesis and transfected each mutant tubulin separately into HEK and/or HeLa cells. We found that a Q291M βI-tubulin mutation increased sensitivity of the cells to PLA, but not to LAU, paclitaxel (PTX), or vinblastine (VBL). In contrast, V333W and N337L mutations led to less stable microtubules, with the V333W causing resistance to PLA and PTX, but not LAU, and the N337L causing resistance to PLA, LAU, and PTX. Moreover, cells expressing either W333 or L337 were hypersensitive to the microtubule-destabilizing agent, VBL. The D295I mutation conferred resistance to both PLA and LAU without affecting microtubule stability or sensitivity to PTX or ixabepilone (IXB). This study identifies the first mammalian βI-tubulin mutation that specifically increases sensitivity to PLA, and reports mutations at PLA and LAU binding site residues that can either reduce microtubule stability or impair drug-tubulin binding, conferring resistance to these microtubule-stabilizing agents. This information provides insights on β-tubulin residues important for maintaining microtubule structural integrity and for sensitivity to microtubule-targeting agents, and suggests novel directions for rational structure-based design of new and more potent agents for cancer treatment that target the LAU/PLA site.
Collapse
|
8
|
Wender PA, Donnelly AC, Loy BA, Near KE, Staveness D. Rethinking the Role of Natural Products: Function-Oriented Synthesis, Bryostatin, and Bryologs. METHODS AND PRINCIPLES IN MEDICINAL CHEMISTRY 2014. [DOI: 10.1002/9783527676545.ch14] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
9
|
|
10
|
Kotha S, Goyal D, Chavan AS. Diversity-Oriented Approaches to Unusual α-Amino Acids and Peptides: Step Economy, Atom Economy, Redox Economy, and Beyond. J Org Chem 2013; 78:12288-313. [DOI: 10.1021/jo4020722] [Citation(s) in RCA: 83] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Sambasivarao Kotha
- Department
of Chemistry, Indian Institute of Technology Bombay Powai, Mumbai 400 076, India
| | - Deepti Goyal
- Department
of Chemistry, Indian Institute of Technology Bombay Powai, Mumbai 400 076, India
| | - Arjun S. Chavan
- Department
of Chemistry, Indian Institute of Technology Bombay Powai, Mumbai 400 076, India
| |
Collapse
|
11
|
Gajewski MM, Tuszynski JA, Barakat K, Huzil JT, Klobukowski M. Interactions of laulimalide, peloruside, and their derivatives with the isoforms of β-tubulin. CAN J CHEM 2013. [DOI: 10.1139/cjc-2012-0360] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The investigational anticancer agents laulimalide and peloruside are known to exert an antimitotic effect on cells by binding to β-tubulin. The binding affinities of derivatives of laulimalide and peloruside to all known isoforms of human β-tubulin were calculated using molecular mechanical, molecular dynamical, and quantum mechanical methods. Several of the derivatives are predicted to have improved β-tubulin binding affinities compared to the parent structures. These results can form the starting point for developing laulimalide or peloruside derivatives with greater specificity for the particular β-tubulin isoforms, which are overexpressed in certain tumours.
Collapse
Affiliation(s)
- Melissa M. Gajewski
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
- Division of Experimental Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - Jack A. Tuszynski
- Division of Experimental Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada
- Department of Physics, University of Alberta, Edmonton, AB, Canada
| | - Khaled Barakat
- Division of Experimental Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | - J. Torin Huzil
- School of Pharmacy and Department of Applied Mathematics, University of Waterloo, Waterloo, ON, Canada
| | | |
Collapse
|
12
|
Ayoub AT, Klobukowski M, Tuszynski J. Similarity-based virtual screening for microtubule stabilizers reveals novel antimitotic scaffold. J Mol Graph Model 2013; 44:188-96. [PMID: 23871820 DOI: 10.1016/j.jmgm.2013.05.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2013] [Revised: 05/25/2013] [Accepted: 05/27/2013] [Indexed: 11/29/2022]
Abstract
Microtubules are among the most studied and best characterized cancer targets identified to date. Many microtubule stabilizers have been introduced so far that work by disrupting the dynamic instability of microtubules causing mitotic block and apoptosis. However, most of these molecules, especially taxol and epothilone, suffer absorption, toxicity and/or resistance problems. Here we employ a novel similarity-based virtual screening approach in the hope of finding other microtubule stabilizers that perform better and have lower toxicity and resistance. Epothilones, discodermolide, eleutherobin and sarcodictyin A have been found to compete with taxanes for the β-tubulin binding site, which suggests common chemical features qualifying for that. Our approach was based on similarity screening against all these compounds and other microtubule stabilizers, followed by virtual screening against the taxol binding site. Some novel hits were found, together with a novel highly rigid molecular scaffold. After visual manipulations, redocking and rescoring of this novel scaffold, its affinity dramatically increased in a promising trend, which qualifies for biological testing.
Collapse
Affiliation(s)
- Ahmed T Ayoub
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | | | | |
Collapse
|
13
|
Uenishi J, Kawai N. Stereochemistry and Synthetic Applications of Intramolecular Chirality Transfer Reaction Promoted by PdII-catalyst. J SYN ORG CHEM JPN 2013. [DOI: 10.5059/yukigoseikyokaishi.71.912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
14
|
Peloruside, Laulimalide, and Noscapine Interactions with Beta-Tubulin. Pharm Res 2012; 29:2985-93. [DOI: 10.1007/s11095-012-0809-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2012] [Accepted: 06/11/2012] [Indexed: 02/04/2023]
|
15
|
Wender PA, Loy BA, Schrier AJ. Translating Nature's Library: The Bryostatins and Function-Oriented Synthesis. Isr J Chem 2011; 51:453-472. [PMID: 22661768 PMCID: PMC3364006 DOI: 10.1002/ijch.201100020] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We review in part our computational, design, synthesis, and biological studies on a remarkable class of compounds and their designed analogs that have led to preclinical candidates for the treatment of cancer, a first-in-class approach to Alzheimer's disease, and a promising strategy to eradicate HIV/AIDS. Because these leads target, in part, protein kinase C (PKC) isozymes, they have therapeutic potential even beyond this striking set of therapeutic indications. This program has given rise to new synthetic methodology and represents an increasingly important direction of synthesis focused on achieving function through synthesis-informed design (function-oriented synthesis).
Collapse
Affiliation(s)
- Paul A. Wender
- Department of Chemistry Department of Chemical and Systems Biology Stanford University Stanford, CA 94305, USA
| | - Brian A. Loy
- Department of Chemistry Department of Chemical and Systems Biology Stanford University Stanford, CA 94305, USA
| | - Adam J. Schrier
- Department of Chemistry Department of Chemical and Systems Biology Stanford University Stanford, CA 94305, USA
| |
Collapse
|
16
|
Wang J, Sintim HO. Dialkylamino-2,4-dihydroxybenzoic Acids as Easily Synthesized Analogues of Platensimycin and Platencin with Comparable Antibacterial Properties. Chemistry 2011; 17:3352-7. [DOI: 10.1002/chem.201002410] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2010] [Revised: 12/14/2010] [Indexed: 11/08/2022]
|
17
|
Ghosh AK. Capturing the essence of organic synthesis: from bioactive natural products to designed molecules in today's medicine. J Org Chem 2010; 75:7967-89. [PMID: 20936876 PMCID: PMC2993809 DOI: 10.1021/jo101606g] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In this Perspective, I outline my group's research involving the chemical syntheses of medicinally important natural products, exploration of their bioactivity, and the development of new asymmetric carbon-carbon bond-forming reactions. This paper also highlights our approach to molecular design and synthesis of conceptually novel inhibitors against target proteins involved in the pathogenesis of human diseases, including AIDS and Alzheimer's disease.
Collapse
Affiliation(s)
- Arun K Ghosh
- Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, USA.
| |
Collapse
|
18
|
Nguyen TL, Xu X, Gussio R, Ghosh AK, Hamel E. The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [³H]peloruside A. J Chem Inf Model 2010; 50:2019-28. [PMID: 21028850 DOI: 10.1021/ci1002894] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We used synthetic peloruside A for the commercial preparation of [³H]peloruside A. The radiolabeled compound bound to preformed tubulin polymer in amounts stoichiometric with the polymer's tubulin content, with an apparent K(d) value of 0.35 μM. A less active peloruside A analogue, (11-R)-peloruside A and laulimalide acted as competitive inhibitors of the binding of the [³H]peloruside A, with apparent K(i) values of 9.3 and 0.25 μM, respectively. Paclitaxel, epothilone B, and discodermolide had essentially no ability to inhibit [³H]peloruside A binding, confirming that these compounds bind to a different site on tubulin polymer. We modeled both laulimalide and peloruside A into the binding site on β-tubulin that was identified by Huzil et al. (J. Mol. Biol. 2008, 378, 1016-1030), but our model provides a more reasonable structural basis for the protein-ligand interaction. There is a more complete desolvation of the peloruside A ligand and a greater array of favorable hydrophobic and electrostatic interactions exhibited by peloruside A at its β-tubulin binding site. In addition, the protein architecture in our peloruside A binding model was suitable for binding laulimalide. With the generation of both laulimalide and peloruside A binding models, it was possible to delineate the structural basis for the greater activity of laulimalide relative to peloruside A and to rationalize the known structure-activity relationship data for both compounds.
Collapse
Affiliation(s)
- Tam Luong Nguyen
- Target Structure-Based Drug Discovery Group, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
| | | | | | | | | |
Collapse
|
19
|
Bennett MJ, Barakat K, Huzil JT, Tuszynski J, Schriemer DC. Discovery and Characterization of the Laulimalide-Microtubule Binding Mode by Mass Shift Perturbation Mapping. ACTA ACUST UNITED AC 2010; 17:725-34. [DOI: 10.1016/j.chembiol.2010.05.019] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2010] [Revised: 05/06/2010] [Accepted: 05/10/2010] [Indexed: 01/25/2023]
|
20
|
The chemistry of the carbon-transition metal double and triple bond: Annual survey covering the year 2008. Coord Chem Rev 2010. [DOI: 10.1016/j.ccr.2009.07.018] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
21
|
Gollner A, Altmann KH, Gertsch J, Mulzer J. Synthesis and biological evaluation of a des-dihydropyran laulimalide analog. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2009.07.122] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|